News | Peripheral Artery Disease (PAD) | September 20, 2017

Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries

CBSET data published in Journal of Controlled Release

Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries

September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published data and analyses providing critical insights into the barrier effects of calcified plaque on drug delivery and the treatment success of adjunctive lesion preparation therapy.

“This preclinical demonstration of the hindrance of drug distribution by calcified tissue and improved drug delivery after modification of calcified atherosclerotic plaque could have significant clinical implications,” said Michael R. Jaff, D.O., president, Newton-Wellesley Hospital, and professor of medicine, Harvard Medical School.

These data demonstrate enhanced paclitaxel distribution in calcified human arteries after lesion treatment using the Diamondback 360 orbital atherectomy system in a cadaver model with simulated flow and are published in the online Journal of Controlled Release.

“These data suggest that clinical association of diminished efficacy of anti-restenotic drugs in severely calcified arteries is at least partly due to limitations in drug absorption,” Jaff continued.

“The data are exciting in that they suggest that subtle modification to the plaque surface can have profound effects on drug penetration. Massive debulking may be a relic of the past, and a more muted approach may extend endovascular intervention for PAD [peripheral artery disease] treatment into vessels even below the knee,” said Elazer Edelman, M.D., Ph.D., chairman and co-founder of CBSET, and senior author of the paper. “This paradigm shift, which relies on quantitative studies, creates an opportunity for the medical device industry to optimize drug delivery therapies to complex lesions.”

Watch the VIDEO "State of Therapy for Critical Limb Ischemia," an interview with Jaff at ACC.16.

For more information: www.sciencedirect.com


Related Content

News | Atherectomy Devices

Medtronic recently announced results from two studies evaluating the utility of atherectomy for peripheral endovascular ...

Home November 08, 2024
Home
News | Atherectomy Devices

February 15, 2023 — Abbott and Cardiovascular Systems, Inc. (CSI), announced a definitive agreement for Abbott to ...

Home February 15, 2023
Home
News | Atherectomy Devices

July 28, 2022 — Northeast Scientific Inc., pioneers in reprocessing single use peripheral vascular catheters, announced ...

Home July 28, 2022
Home
News | Atherectomy Devices

March 9, 2022 — Medtronic is recalling (correcting) the TurboHawk Plus Directional Atherectomy System due to design ...

Home March 09, 2022
Home
News | Atherectomy Devices

January, 24, 2022 — Medtronic Inc. is recalling its HawkOne Directional Atherectomy System product due to the risk of ...

Home January 24, 2022
Home
News | Atherectomy Devices

January 10, 2022 — Cardiovascular Systems Inc. (CSI) is recalling the Wirion atherectomy embolic protection device ...

Home January 10, 2022
Home
News | Atherectomy Devices

July 20, 2020 – BD (Becton, Dickinson and Company) recently completed the acquisition of Straub Medical AG, a privately ...

Home July 20, 2020
Home
News | Atherectomy Devices

February 13, 2020 — The U.S. Food and Drug Administration (FDA) has issued its final guidance on "Peripheral Vascular ...

Home February 13, 2020
Home
News | Atherectomy Devices

November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and ...

Home November 11, 2019
Home
News | Atherectomy Devices

November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs. plain old balloon angioplasty (POBA) ...

Home November 07, 2019
Home
Subscribe Now